Kiromic Biopharma, Inc. — key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2024)

$0

Net Income/Loss (FY2024)

-$26.9M

Total Assets (FY2024)

$8.5M

Total Equity (FY2024)

-$12.6M

Cash Flows from Operating Activities (FY2024)

-$19.5M

Source: Kiromic Biopharma, Inc. 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.